{"url_path":"/sec/cdna/8-k/2026-07-07/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-07","source_url":"https://www.sec.gov/Archives/edgar/data/1217234/0001217234-26-000038-index.html","accession_number":"0001217234-26-000038","cik":"0001217234","ticker":"CDNA","issuer_name":"CareDx, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1217234/0001217234-26-000038-index.html","primary_entity_key":"0001217234","primary_entity_name":"CareDx, Inc."},"word_count":400,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(a) Financial Statements of Business Acquired.\n\nThe financial statements of Naveris required to be filed under Item 9.01(a) of this Current Report on Form 8-K in connection with the Naveris Transaction will be filed by amendment to this Current Report on Form 8-K no later than 71 calendar days after the date on which this Current Report on Form 8-K is required to be filed.\n\n(b) Pro Forma Financial Information.\n\nThe pro forma financial information required to be filed under Item 9.01(b) of this Current Report on Form 8-K in connection with the Naveris Transaction will be filed by amendment to this Current Report on Form 8-K no later than 71 calendar days after the date on which this Current Report on Form 8-K is required to be filed.\n\n(d) Exhibits.\n\nExhibit No.\n\n \n\nDescription\n\n2.1+*\n\n \n\n[Purchase Agreement, dated April 15, 2026 by and between CareDx, Inc. and Eurobio Scientific S.A. (filed as Exhibit 2.1 to the Registrant's Current Report on Form 8-K as filed on April 16, 2026).](https://www.sec.gov/Archives/edgar/data/1217234/000110465926043970/tm2611749d1_ex2-1.htm)\n\n2.2+*\n\n[Agreement and Plan of Merger, dated April 28, 2026 by and among CareDx, Inc., Nautilus Merger Sub, Inc., Naveris, Inc. and Shareholder Representative Services LLC, solely in its capacity as the representative of the securityholders of Naveris, Inc. (filed as Exhibit 2.1 to the Registrant's Current Report on Form 8-K as filed on April 28, 2026).](https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/tm2611749d3_ex2-1.htm)\n\n99.1\n\n[Press Release issued by CareDx, Inc., dated June 30, 2026 (Eurobio).](quark-pressrelease.htm)\n\n99.2\n\n[Press Release issued by CareDx, Inc., dated July 1, 2026 (Naveris).](naveris-pressrelease.htm)\n\n104\n\nCover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).\n\n+         Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because they are both (i) not material and (ii) are the type of information the Registrant customarily and actually treats as private or confidential.\n\n*        Certain schedules and attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to provide, on a supplemental basis, a copy of any omitted schedules and attachments to the Securities and Exchange Commission or its staff upon request.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nCAREDX, INC.\n\nDate: July 7, 2026\n\nBy:\n\n \n\n/s/ JOHN HANNA\n\n \n\nJohn W. Hanna\n\n \n\nPresident, Chief Executive Officer and Director"}